Alcidion Group Limited (ALC) AI Stock Analysis

• Market Cap: AU$134.30M
• Dividend Yield: N/A
• Average Volume (3M): 793.40K
• Price to Earnings (P/E): 79.2
• Beta (1Y): 0.82
• Revenue Growth: 10.06%
• EPS Growth: N/A
• Country: AU
• Employees: 145
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): <0.01
• Shares Outstanding: 1,342,952,600
• 10 Day Avg. Volume: 607,354
• 30 Day Avg. Volume: 793,401
• PEG Ratio: -0.70
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 3.38
• P/FCF Ratio: 24.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.12
• Price Target Upside: 20.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 58 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Alcidion Group Limited's overall stock score is primarily driven by its strong financial performance, characterized by robust revenue growth and efficient cost management. However, the high P/E ratio suggests potential overvaluation, and technical indicators point to a lack of strong momentum. The absence of a dividend yield further impacts the valuation score.

Alcidion Group Limited Business Overview & Revenue Model

Company Description

Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; Silverlink, a patient administration system; and ExtraMed, a clinical and patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.

How the Company Makes Money

Alcidion Group Limited generates revenue primarily through the sale of software licenses, subscriptions, and related services to healthcare providers. The company offers a recurring revenue model through annual subscriptions for its cloud-based solutions, providing a steady income stream. Key revenue streams also include implementation services, training, and support services provided to clients post-sale. Additionally, Alcidion has formed strategic partnerships with various healthcare organizations and technology firms, which enhance its market presence and can lead to new business opportunities. Factors contributing to its earnings include the increasing demand for digital health solutions, particularly in response to the challenges faced by healthcare systems globally, and ongoing investments in product development to maintain competitiveness in the evolving health tech landscape.

Alcidion Group Limited Financial Statement Overview

Summary

Alcidion Group Limited shows strong revenue growth and efficient cost management with a high gross profit margin. The company maintains a stable financial position with low debt levels, enhancing its financial flexibility. However, profitability margins are relatively low, and operational challenges are indicated by a negative EBIT margin. The significant improvement in cash flow metrics highlights strong cash generation capabilities.

Income Statement

Alcidion Group Limited has shown a positive revenue growth rate of 14.45% in the latest year, indicating a strong upward trajectory. The gross profit margin is high at 88.24%, reflecting efficient cost management. However, the net profit margin is relatively low at 4.06%, suggesting limited profitability. The EBIT margin is negative, indicating operational challenges, but the EBITDA margin is positive, showing some improvement in operational efficiency.

Balance Sheet

The company maintains a very low debt-to-equity ratio of 0.016, indicating strong financial stability and low leverage risk. The return on equity is modest at 1.88%, suggesting limited profitability from shareholders' investments. The equity ratio is not provided, but the overall balance sheet reflects a stable financial position with low debt levels.

Cash Flow

Alcidion Group Limited has demonstrated a significant improvement in free cash flow growth, with a remarkable increase of 3584.97%. The operating cash flow to net income ratio is 0.28, indicating a healthy conversion of income into cash. The free cash flow to net income ratio is high at 0.98, showing strong cash generation relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.79M	40.79M	37.06M	40.40M	34.35M	25.88M
Gross Profit	35.99M	35.99M	31.92M	1.25M	3.29M	3.52M
EBITDA	1.94M	1.94M	-4.50M	-1.43M	-1.58M	-474.00K
Net Income	1.65M	1.65M	-8.42M	-3.62M	-4.41M	-2.24M
Balance Sheet
Total Assets	115.63M	115.63M	114.46M	120.68M	128.35M	58.38M
Cash, Cash Equivalents and Short-Term Investments	17.70M	17.70M	11.80M	14.64M	17.34M	25.03M
Total Debt	1.41M	1.41M	1.70M	2.15M	2.48M	181.00K
Total Liabilities	27.82M	27.82M	27.52M	30.52M	34.40M	13.16M
Stockholders Equity	87.80M	87.80M	86.94M	90.17M	93.95M	45.22M
Cash Flow
Free Cash Flow	5.64M	5.64M	-7.18M	-285.00K	685.00K	1.23M
Operating Cash Flow	5.76M	5.76M	-7.13M	169.00K	996.00K	1.54M
Investing Cash Flow	-125.00K	-125.00K	-53.00K	-3.14M	-59.74M	-9.84M
Financing Cash Flow	-764.00K	-764.00K	4.34M	-616.00K	51.33M	17.23M

Alcidion Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 111.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.

Alcidion Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	58 Neutral	AU$134.30M	79.17	1.89%	―	10.06%	―
PCK	55 Neutral	AU$118.13M	―	-8647.54%	―	25.98%	21.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
M7T	49 Neutral	$70.49M	―	-12.35%	―	15.99%	22.05%
BMT	47 Neutral	AU$61.03M	―	-13.83%	―	3.61%	-17.03%
ONE	44 Neutral	$137.40M	―	―	―	21.56%	-24.08%
SHG	40 Underperform	AU$92.20M	―	―	―	―	―

Alcidion Group Limited Corporate Events

Alcidion Group Updates Securities Trading Policy

Alcidion Group Limited has announced a revision to its Securities Trading Policy in compliance with ASX Listing Rule 12.10. This update is part of the company’s ongoing efforts to maintain robust corporate governance practices. The revised policy is available on Alcidion’s website, reflecting the company’s commitment to transparency and regulatory compliance, which is crucial for its stakeholders and market positioning.

The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.09 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group Achieves Record Cash Flow and Expands Key Contracts in Q4 FY25

Alcidion Group Limited reported a record-breaking quarter with a positive operating cash flow of $7.4 million, marking the highest in the company’s history. The company achieved significant growth in new sales and contract expansions, notably with North Cumbria Integrated Care NHS Trust, which increased the total contract value to over $39 million. Alcidion ended the fiscal year with a cash balance of $17.7 million and no debt, demonstrating a strong financial position. The company’s continued expansion and deployment of its Miya Precision platform underscore its long-term value proposition and market momentum.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group to Release Q4 FY25 Results and Host Investor Webcast

Alcidion Group Limited announced it will release its Q4 FY25 financial results and host an investor webcast on July 24, 2025. The webcast will feature discussions by the Group Managing Director and CEO, Kate Quirke, and CFO, Matthew Gepp, on the company’s operational and commercial highlights for the quarter. This announcement underscores Alcidion’s commitment to transparency with its stakeholders and its strategic focus on expanding its influence in the global healthcare market.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group Boosts FY25 Financial Guidance Amid Strong Performance

Alcidion Group Limited has upgraded its financial guidance for the fiscal year ending June 2025, expecting EBITDA to exceed $4.5 million, up from the previous forecast of over $3.0 million. This improvement is attributed to smaller contract upgrades, extensions, diligent cost management, and favorable foreign exchange movements. The company’s Miya platform continues to gain traction, leading to increased customer engagement and new opportunities, reinforcing Alcidion’s long-term value proposition and ability to address critical challenges in global hospital systems.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group Limited Announces Cessation of Performance Rights

Alcidion Group Limited announced the cessation of 206,458 performance rights due to the lapse of conditional rights that were not satisfied by the specified date. This development may impact the company’s capital structure and could have implications for stakeholders as it reflects on the company’s performance metrics and strategic objectives.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Announces Board Change with Director Departure

Alcidion Group Limited has announced a change in its board of directors, with Victoria Weekes ceasing to be a director as of May 30, 2025. This update, in compliance with ASX Listing Rule 3.19A.3, is part of the company’s ongoing corporate governance and may impact its strategic direction as it continues to expand its healthcare technology services globally.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.